


AMENDMENTS

This listing of claims will replace all prior versions, and listing, of claims in the application:


In the Claims:

Claims 1-37 (cancelled)

Claim 38 (currently amended): A valency platform molecule having the structure:



where n is about 503; or



wherein n is about 481.

Claims 39-45 (cancelled)

Claim 46 (previously presented): A conjugate of a molecule of claim 38 and one or more biologically active molecules.

Claim 47-53 (cancelled)

Claim 54 (currently amended): The conjugate of claim 46 ~~claim 44 or 45~~ wherein the biologically active molecules are selected from the group consisting of: oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, enzymes, hormones, drugs, nucleic acids, lipids, fatty acids, and mixtures thereof.


Claim 55 (previously presented): The conjugate of claim 54, wherein the biologically active molecules comprise a domain 1 polypeptide of β 2GPI.

Claim 56 (previously presented): The conjugate of claim 55, wherein the polypeptide lacks a T cell epitope.

Claim 57 (previously presented): The conjugate of claim 55, wherein the conjugate comprises a linker that attaches the domain 1 polypeptide of β 2GPI to the valency platform molecule.

Claims 58-65 (cancelled)

Claim 66 (currently amended): A valency platform molecule ~~of claim 16~~ having the structure:



wherein the $(CH_2CH_2O)_n$ moiety has a molecular weight of about 20K g/mol.

Claim 67 (previously presented): A conjugate comprising a molecule of claim 66 and one or more biologically active molecules.

Claim 68 (previously presented): The conjugate of claim 67, wherein the biologically active molecules are selected from the group consisting of oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, enzymes, hormones, drugs, nucleic acids, lipids, fatty acids, and mixtures thereof.


Claim 69 (previously presented): The conjugate of claim 68, wherein the biologically active molecules comprise a domain 1 polypeptide of β 2GPI.

Claim 70 (previously presented): The conjugate of claim 69, wherein the polypeptide lacks a T cell epitope.

Claim 71 (previously presented): The conjugate of claim 69, wherein the conjugate comprises a linker that attaches the domain 1 polypeptide of β 2GPI to the valency platform molecule.

Claims 72-81 (cancelled)

Claim 82 (currently amended): A valency platform molecule of claim 16 having the formula:



wherein n is about 200 to about 500.

Claim 83 (currently amended): A conjugate comprising a valency platform molecule of claim 82 ~~any one of claims 80, 81 or 82~~ and one or more biologically active molecules.

Claim 84 (previously presented): The conjugate of claim 83, wherein the biologically active molecules are selected from the group consisting of oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, enzymes, hormones, drugs, nucleic acids, lipids, fatty acids, and mixtures thereof.

Claim 85 (previously presented): The conjugate of claim 84, wherein the biologically active molecules comprise a domain 1 polypeptide of β 2GPI.

Claim 86 (previously presented): The conjugate of claim 85, wherein the polypeptide lacks a T cell epitope.

Claim 87 (previously presented): The conjugate of claim 85, wherein the conjugate comprises a linker that attaches the domain 1 polypeptide of β 2GPI to the valency platform molecule.

Claim 88 (cancelled)

Claim 89 (currently amended): A method of making the conjugate according to claim 46 ~~claim 44~~, comprising: covalently bonding biologically active molecules to a valency platform molecule such that an oxime bond, or modified form thereof, is formed.

Claim 90 (previously presented): The method of claim 89, wherein the modified oxime bond is a reduced or alkylated oxime bond.

Claim 91 (previously presented): The method of claim 89, wherein the valency platform molecule comprises an aminoxy group and the biologically active molecules comprise a reactive functional group such that an oxime bond is formed upon bonding the biologically active molecules to the valency platform molecule.

Claim 92 (previously presented): The method of claim 91, wherein the reactive functional group is a carbonyl group of an aldehyde or ketone moiety.

Claim 93 (previously presented): The method of claim 92, wherein the biologically active molecules comprise a polypeptide; and, wherein the method comprises modifying the polypeptide prior to bonding with an aminooxy group on the valency platform molecule, such that the polypeptide comprises a terminal aldehyde group.

Claims 94-107 (cancelled)

Claim 108 (currently amended): The valency platform molecule of claim 38 ~~claims 16, 21, 26 or 36~~, wherein the valency platform molecule comprises one or more bivalent linker molecules that may be used for linking a biologically active molecule to the valency platform molecule, wherein the linker molecules comprise aminooxy groups that are optionally protected with an aminooxy protecting group, and wherein the bivalent linker molecules are bonded to the valency platform molecule such that a linkage bond is formed between the divalent linker molecule and the valency platform molecule.

Claim 109 (previously presented): The valency platform molecule of claim 108, wherein the linkage bond that is formed is selected from the group consisting of: an amide linkage, a carbamate linkage, a thioether linkage and an oxime linkage.

Claim 110 (previously presented): The valency platform molecule of claim 109, wherein the linkage bond is formed by reacting the valency platform molecule with the bivalent linker molecule, wherein the bivalent linker molecule comprises a functional moiety that is selected from the group consisting of: amine, acid carbonate ester, thiol, aminooxy, and carboxylic acid.

Claims 111-118 (cancelled)

Claim 119 (currently amended): A pharmaceutical composition comprising the conjugate of claim 46 ~~any of claims 44, 45, 66, 76, 80, 98 or 114~~ and a pharmaceutically acceptable carrier.

Claims 120-123 (cancelled)

Claim 124 (currently amended): A composition comprising two or more valency platform molecules according to claim 38 ~~claim 29~~, wherein the valency platform molecules have a polydispersity less than about 1.2.

Claim 125 (cancelled)

Claim 126 (currently amended): The conjugate of claim 54 ~~claims 44, 45, 61, 68, 74, 97, 114 or 121~~, wherein the biologically active molecules comprise a polypeptide.

Claim 127 (currently amended): The conjugate of claim 54 ~~claims 44, 45, 61, 68, 74, 97, 114 or 121~~, wherein the biologically active molecules comprise a nucleic acid.

Claim 128 (currently amended): The conjugate of claim 54 ~~claims 44, 45, 61, 68, 74, 97, 114 or 121~~, wherein the biologically active molecules comprise an oligonucleotide.

Claim 129-130 (cancelled)

Claim 131 (new): A method of making the conjugate according to claim 67, comprising: covalently bonding biologically active molecules to a valency platform molecule such that an oxime bond, or modified form thereof, is formed.

Claim 132 (new): The method of claim 131, wherein the modified oxime bond is a reduced or alkylated oxime bond.

Claim 133 (new): The method of claim 131, wherein the valency platform molecule comprises an aminooxy group and the biologically active molecules comprise a reactive functional group such that an oxime bond is formed upon bonding the biologically active molecules to the valency platform molecule.

Claim 134 (new): The method of claim 133, wherein the reactive functional group is a carbonyl group of an aldehyde or ketone moiety.

Claim 135 (new): The method of claim 134, wherein the biologically active molecules comprise a polypeptide; and, wherein the method comprises modifying the polypeptide prior to bonding with an aminooxy group on the valency platform molecule, such that the polypeptide comprises a terminal aldehyde group.

Claim 136 (new): A method of making the conjugate according to claim 83, comprising: covalently bonding biologically active molecules to a valency platform molecule such that an oxime bond, or modified form thereof, is formed.

Claim 137 (new): The method of claim 136, wherein the modified oxime bond is a reduced or alkylated oxime bond.

Claim 138 (new): The method of claim 136, wherein the valency platform molecule comprises an aminooxy group and the biologically active molecules comprise a reactive functional group such that an oxime bond is formed upon bonding the biologically active molecules to the valency platform molecule.

Claim 139 (new): The method of claim 138, wherein the reactive functional group is a carbonyl group of an aldehyde or ketone moiety.

Claim 140 (new): The method of claim 139, wherein the biologically active molecules comprise a polypeptide; and, wherein the method comprises modifying the polypeptide

prior to bonding with an aminooxy group on the valency platform molecule, such that the polypeptide comprises a terminal aldehyde group.

Claim 141 (new): The valency platform molecule of claim 66, wherein the valency platform molecule comprises one or more bivalent linker molecules that may be used for linking a biologically active molecule to the valency platform molecule, wherein the linker molecules comprise aminooxy groups that are optionally protected with an aminooxy protecting group, and wherein the bivalent linker molecules are bonded to the valency platform molecule such that a linkage bond is formed between the divalent linker molecule and the valency platform molecule.

Claim 142 (new): The valency platform molecule of claim 141, wherein the linkage bond that is formed is selected from the group consisting of: an amide linkage, a carbamate linkage, a thioether linkage and an oxime linkage.

Claim 143 (new): The valency platform molecule of claim 142, wherein the linkage bond is formed by reacting the valency platform molecule with the bivalent linker molecule, wherein the bivalent linker molecule comprises a functional moiety that is selected from the group consisting of: amine, acid carbonate ester, thiol, aminooxy, and carboxylic acid.

Claim 144 (new): The valency platform molecule of claim 82, wherein the valency platform molecule comprises one or more bivalent linker molecules that may be used for linking a biologically active molecule to the valency platform molecule, wherein the linker molecules comprise aminooxy groups that are optionally protected with an aminooxy protecting group, and wherein the bivalent linker molecules are bonded to the valency platform molecule such that a linkage bond is formed between the divalent linker molecule and the valency platform molecule.

Claim 145 (new): The valency platform molecule of claim 144, wherein the linkage bond that is formed is selected from the group consisting of: an amide linkage, a carbamate linkage, a thioether linkage and an oxime linkage.

Claim 146 (new): The valency platform molecule of claim 145, wherein the linkage bond is formed by reacting the valency platform molecule with the bivalent linker molecule, wherein the bivalent linker molecule comprises a functional moiety that is selected from the group consisting of: amine, acid carbonate ester, thiol, aminooxy, and carboxylic acid.

Claim 147 (new): A pharmaceutical composition comprising the conjugate of claim 67 and a pharmaceutically acceptable carrier.

Claim 148 (new): A composition comprising two or more valency platform molecules according to claim 66, wherein the valency platform molecules have a polydispersity less than about 1.2.

Claim 149 (new): A pharmaceutical composition comprising the conjugate of claim 83 and a pharmaceutically acceptable carrier.

Claim 150 (new): A composition comprising two or more valency platform molecules according to claim 82, wherein the valency platform molecules have a polydispersity less than about 1.2.

Claim 151 (new): The conjugate of 68, wherein the biologically active molecules comprise a polypeptide.

Claim 152 (new): The conjugate of claim 68, wherein the biologically active molecules comprise a nucleic acid.

Claim 153 (new): The conjugate of claim 68, wherein the biologically active molecules comprise an oligonucleotide.

Claim 154 (new): The conjugate of claim 84, wherein the biologically active molecules comprise a polypeptide.

Claim 155 (new): The conjugate of claim 84, wherein the biologically active molecules comprise a nucleic acid.

Claim 156 (new): The conjugate of claim 84, wherein the biologically active molecules comprise an oligonucleotide.

Claim 157 (new): A pharmaceutical composition comprising the conjugate of claim 55 and a pharmaceutically acceptable carrier.

Claim 158 (new): A pharmaceutical composition comprising the conjugate of claim 56 and a pharmaceutically acceptable carrier.

Claim 159 (new): A pharmaceutical composition comprising the conjugate of claim 69 and a pharmaceutically acceptable carrier.

Claim 160 (new): A pharmaceutical composition comprising the conjugate of claim 70 and a pharmaceutically acceptable carrier.

Claim 161 (new): A pharmaceutical composition comprising the conjugate of claim 85 and a pharmaceutically acceptable carrier.

Claim 162 (new): A pharmaceutical composition comprising the conjugate of claim 86 and a pharmaceutically acceptable carrier.